B1. Colantoni A, De Maria N, Idilman R, Barve SJ, Barve S, Mc Clain CJ, Kugelmas M, Van Theil DH. “Salicylate prevents hypoxia-reperfusion injury in liver without inhibiting NF-kB activation.” 15th Annual Scientific Meeting, The American Society of Transplant Physicians, 542, Chicago, IL-USA, 1997.

B2. De Maria N, Colantoni A, Wu Q, Zhu Q, Idilman R, Van Theil DH. “Comparison between University of Wisconsin solution and Euro-Collins plus sodium salicylate for cold preservation of rat livers.” 48th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 354, Chicago, IL-USA, 1997.

B3. Gürman G, Arslan Ö, Koç H, Dilek İ, Üstün C, Özcan M, Akan H, İlhan O, Sunguroğlu A, Konuk N, Uysal A, Idilman R, Beksaç M. “Donor leukocyte infusions for the treatment of leukemia relapse after allogeneic hematopoietic progenitor cell transplantation.” 39th Annual Meeting, American Society of Hematology, 379, San Diego, CA-USA, 1997.

B4. Üstün C, Idilman R, Gürman G, Özcan M, Akyol G, Akan H, İlhan O, Beksaç M, Uysal A, Konuk N, Van Theil DH, Karayalçın S, Koç H. “Stem cell transplantaion in non-replicative as compared to replicative hepatitis B virus carriers is safe.” 1st Hepatology Day, European Association For The Study Of The Liver (EASL) Postgraduate Course, 132, İstanbul-Turkey, 1998.

B5. Uzunalimoğlu Ö, Bozdayı M, Dökmeci A, Şengezer T, Erkan Ö, Idilman R, Altınbaş B, Arıcan A, Çağsın S, Bahar K. “Hepatitis G virus infection among hemodialysis patients and patients with thalassemia major and patients with hematologic malignancy in Turkey.” 1st Hepatology Day, European Association For The Study Of The Liver (EASL) Postgraduate Course, 145, İstanbul-Turkey, 1998.

B6. Dilek İ, Idilman R, Akan H, Fenkçi S, Üstün C, Koç H, İlhan O. “Immunosuppressive therapy-induced hepatotoxicity.” 1st Hepatology Day, European Association For The Study Of The Liver (EASL) Postgraduate Course, 180, İstanbul-Turkey, 1998.

B7. Özden A, Çetinkaya H, Idilman R, Türkay C, Bahar K, Soykan İ. “Kısa süreli üçlü kombine tedavinin Helicobacter Pylori erdaikasyonunda yeri.” 2nd Avrasya Gastroenteroloji Günleri, 286, Almatı-Kazakistan, 1998.

B8. Beksaç M, İlhan O, Uysal A, Koç H, Idilman R, Arat M, Üstün C, Özcan M. “Cladribine therapy in chronic lymphoproliferative disorders: Single center experience. ISH-EHA Combined Haematology Congress, 244, Amsterdam-The Netherlands, 1998.

B9. Çetinkaya H, Idilman R, Savaş İ, Baştemir M, Karacan Ö, Sarıoğlu M, Uzunalimoğlu Ö, Dökmeci A, Numanoğlu N. “Bronchoalveolar lavage fluid findings in patients with hepatitis C virus. 49th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 674, Chicago, IL-USA, 1998.

B10. Üstün C, Idilman R, Özcan M, Akan H, Karayalçın S, Gürman G, İlhan O, Beksaç M, Uysal A, Konuk N, Demirer T, Koç H. “Which hematopoietic stem cell transplantation type is safe for patients with hepatitis B virus carriers.” 49th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 718, Chicago, IL-USA, 1998.

B11. Idilman R, Akan H, Üstün C, Bozkaya H, Bozdayı M, Uzunalimoğlu Ö, Dökmeci A, Koç H. “Is there any correlation between transfusion frequency of blood and blood products and hepatitis G virus transmission.” 49th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 728, Chicago, IL-USA, 1998.

B12. Idilman R, Üstün C, Bozkaya H, Bozdayı M, Akan H. “Is there any correlation between transfusion frequency of blood and blood products and blood-borne hepatitis virus transmission.” 40th Annual Meeting, American Society of Hematology, 133, Miami Beach, FL-USA, 1998.

B13. Idilman R, Çetinkaya H, Savaş İ, Baştemir M, Karacan Ö, Sarıoğlu M, Uzunalimoğlu Ö, Dökmeci A, Numanoğlu N. “Lymphocyte population of bronchoalveolar lavage fluid in patient with hepatitis C virus.” 34th Annual Meeting, European Association For The Study Of The Liver (EASL), 261, Naples-Italy, 1999.

B14. Üstün C, Idilman R, Bozkaya H, Çelebi H, Arat M, Coşkun HŞ, Bozdayı M, İlhan O. “Hepatitis G virus in the sera of patients with aplastic anaemia.” 4th Congress of the European Haematology Association (EHA), 1207, Barcelona-Spain, 1999.

B15. Idilman R, Üstün C, Türkyılmaz A, Gürman G, Özcan M, Karayalçın S, Akan H, İlhan O, Beksaç M, Bozdayı M, Van Thiel DH, Koç H. “Adoptive immunity transfer in hepatitis virus carriers with hematological malignancy who undergoing allogeneic hematopoietic stem cell transplantation.” 50th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 640, Chicago, IL-USA, 1999.

B16. Colantoni A, De Maria N, Idilman R, Harig J, Van Thiel DH. “Estrogen status contributes to the gender difference in the response to IFN for chronic hepatitis C.” 35th Annual Meeting, European Association For The Study Of The Liver (EASL), 54, Rotterdam-The Netherlands, 2000.

B17. Idilman R, De Maria N, Colantoni A, Harig J, Van Thiel DH. “HFE mutations in chronic hepatitis C.” 35th Annual Meeting, European Association For The Study Of The Liver (EASL), 10, Rotterdam-The Netherlands, 2000.

B18. Colantoni A, De Maria N, Idilman R, Harig J, Van Thiel DH. “Racial differences in the response to antiviral therapy for chronic hepatitis.” 35th Annual Meeting, European Association For The Study Of The Liver (EASL), 71, Rotterdam-The Netherlands, 2000.

B19. Idilman R, Üstün C, Akan H, Karayalçın S, Özcan M, Arslan Ö, İlhan O, Akyol G, Bozdayı M, Colantoni A, Van Thiel DH. “Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation: Risk and benefit ratio of HBV vaccination in recipients.” 51st Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 455, Dallas, Texas-USA, 2000.

B20. Colantoni A, Duffner LA, Idilman R, Grabowsky KA, Van Thiel DH, Witte PL, Kovacs EJ. “Hypoxia-reoxygenation injury contributes to aging of mouse liver.” 14th Annual Meeting, American Collage of Clinical Gerontology, 29, Boston, MA-USA, 2000.

B21. Idilman R, Colantoni A, De Maria N, Alkan S, Nand S, Soykan İ, Törüner M, Özden A, Dökmeci A, Van Thiel DH. “B-cell lymphoproliferative and plasma cell disorders in individuals with chronic hepatitis C.” 52nd Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 433, Dallas, Texas-USA, 2001.

B22. Örmeci N, Soykan İ, Idilman R, Sarıoğlu M, Palabıyıkoğlu M, Yaşa H, Bektaş A, Beyler A, Dökmeci A, Uzunalimoğlu Ö. “Percutaneous treatment of the hydatid cysts of the liver: The efficacy of ethyl alcohol and polidocanol injection.” 20th International Congress of Hydatidology, 143, Kuşadası-Turkey, 2001.

B23. Örmeci N, Soykan İ, Idilman R, Palabıyıkoğlu M, Uzunalimoğlu Ö. “Percutaneous treatment of the hydatid cysts of the spleen: A new approach.” 20th International Congress of Hydatidology, 144, Kuşadası-Turkey, 2001.

B24. Örmeci N, Idilman R, Soykan İ, Palabıyıkoğlu M, Dökmeci A. “Percutaneous treatment of the hydatid cysts of the kidney.” 20th International Congress of Hydatidology, 316, Kuşadası-Turkey, 2001.

B25. Örmeci N, Soykan İ, Sarıoğlu M, Idilman R, Palabıyıkoğlu M, Karayalçın K. “Percutaneous treatment of the hydatid cysts of the peritoneum.” 20th International Congress of Hydatidology, 317, Kuşadası-Turkey, 2001.

B26. Örmeci N, Soykan İ, Idilman R, Sarıoğlu M, Palabıyıkoğlu M. “Percutaneous treatment of the hydatid cysts of the muscle.” 20th International Congress of Hydatidology, 318, Kuşadası-Turkey, 2001.

B27. Idilman R, Tükün A, Erden E, Arat M, Törüner M, Soykan İ, Kuzu I, Özcan M, Topçuoğlu P, Soydan E, Karayalçın S, Özden A, Akan H. “Repopulation of liver endothelial cells, but not hepatocytes, by hematopoietic cell transplants.” 9th International Symposium on Biomedical Science and Technology, 13, Antalya-Turkey, 2002.

B28. Arat M, Idilman R, Soydan E, Soykan İ, Üstün C, Topçu M, Karayalçın S, Akan H. “The efficiency of ursodeoxycholic acid in treatment of limited chronic graft-versus-host disease of the liver. American Society of Hematology, 5380, 2002.

B29. Örmeci N, Soykan İ, Idilman R, Törüner M, Çınar K, Sarıoğlu M, Palabıyıkoğlu M. “Percutaneous treatment of type III hydatid cysts of the liver: Long-term results. 12th World Congress of The International Association of Surgeons and Gastroenterologists, 94, İstanbul-Turkey, 2002.

B30. Bektaş M, Sarıoğlu M, Idilman R, Soykan İ, Bozkaya H, Özkan H, Beyler AR, Karayalçın S, Yurdaydın C, Örmeci N, Bahar K, Dökmeci A. “Diagnosis of sclerosing cholangitis with ERCP.” 12th World Congress of The International Association of Surgeons and Gastroenterologists, 184, İstanbul-Turkey, 2002.

B31. Soydan E, Arat M, Topcuoğlu P, Özcan M, Arslan Ö, Idilman R, Gurman G, Beksaç M, Akan H, İlhan O. “The effect of mycophenolate mofetil in steroid refractory or dependent chronic graft-verus-host disease.” 29th Annual Meeting of the EBMT, 561, İstanbul-Turkey, 2003.

B32. Kuzu I, Idilman R, Arat M, Dalva K, Soykan İ, Akan H, Beksaç M. “Donor type epithelial cell repopulation in gastrointestinal mucosa following sex mismatch allogeneic peripheral blood transplantation.” 29th Annual Meeting of the EBMT, 816, İstanbul-Turkey, 2003.

B33. Idilman R, Soydan E, Arat M, Törüner M, Soykan İ, Karayalçın S, Üstün C, Topcuoğlu P, Özcan M, Arslan Ö, Beksaç M, İlhan O, Akan H, Özden A. “The effect of hepatitis B virus status of donor on the hepatitis B virus serology of recipient after allogeneic hematopoietic cell transplantation.” 38th Annual Meeting, European Association For The Study Of The Liver (EASL), 146, İstanbul-Turkey, 2003.

B34. Idilman R, Arat M, Törüner M, Soykan İ, Karayalçın S, Soydan E, Özcan M, Beksaç M, Arslan Ö, Akbulut H, İlhan O, Akan H, Özden A. “Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in hepatitis B virus carriers with hematological malignancies.” 38th Annual Meeting, European Association For The Study Of The Liver (EASL), 146, İstanbul-Turkey, 2003.

B35. Idilman R, Kuzu I, Erden E, Ersoz S, Karayalcin K, Yerdel M, Tukun A, Bozkaya H, Yurdaydın C, Karayalcın S. “Recipient-derived hepatocytes in sex-mismatched liver transplants: A preliminary report.” From Stem Cells to Xenotransplantation. European Association For The Study Of The Liver (EASL), 36, Venice-Italy, 2003.

B36. Idilman R, Kuzu I, Erden E, Ersoz S, Karayalcin K, Yerdel M, Tukun A, Bozkaya H, Yurdaydın C, Karayalcın S. “Recipient-derived hepatocytes in sex-mismatched liver transplants.” 54th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 1025, Boston, MA-USA, 2003.

B37. Verdi H, Koytak ES, Ergul AA, Idilman R, Uzunalimoglu O, Yurdaydin C, Bozkaya H. “PPAR-Alpha L162V polymorphism in non-alcoholic steatohepatitis.” 55th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 588, Boston, MA-USA, 2004.

B38. Kuzu I, Idilman R, Arat M, Dalva K, Soykan İ, Akan H, Beksaç M. “Donor type epithelial cell repopulation in gastrointestinal mucosa following sex mismatch allogeneic peripheral blood transplantation: An evidence for in vivo stem cell plasticity? 12th Annual International Symposium on Recent Advances in Stem Cell Transplantation, 5, Heilderberg-Germany, 2004.

B39. Idilman R, Soykan I, Erden E, Kuzu I, Arat M, Akyol G, Akan H, Beksac M, Ozden A, Karayalcin S. “The effect of tissue injury on donor-derived hepatocyte repopulation following sex-mismatched hematopoietic stem cell transplantation.” 40th Annual Meeting of the European Association for the Study of the Liver. (EASL), 139, Paris, France, 2005.

B40. Arslan A, Yurdaydin C, Koytak ES, Idilman R, Uzunalimoglu O, Bozdayi AM, Bozkaya H. “Potential role of cytokine gene polymorphism in hepatitis B infection outcome.” 40th Annual Meeting of the European Association for the Study of the Liver. (EASL), 230, Paris, France, 2005.

B41. Idilman R, Erden E, Arat M, Coban S, Erkan O, Tuzun A, Kuzu I, Bozadayi AM, Akan H, Karayalcin S, Ozden A. “The expression of intestinal trefoil factor in biliary epithelial cells of chronic graft-versus-host disease of the liver in allogeneic hematopoietic stem cell transplants.” 40th Annual Meeting of the European Association for the Study of the Liver. (EASL), 236, Paris, France, 2005.

B42. Yurdaydin C, Bozkaya H, Onder O, Senturk H, Fried M, Idilman R, Cetinkaya H, Schinazi R, Bozdayi AM, Uzunalimoglu O. “Treatment of chronic hepatitis D with interferon vs interferon+lamivudine vs lamivudine. Short- and long-term results.” 56th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 724, San Francisco, CA-USA, 2005.

B43. Idilman R, Erden E, Ersoz S, Kuzu I, Karayalcin S. “The fate of recipient-derived repopulated hepatocytes in sex-mismatched liver allograft: a longitudinal study. Short- and long-term results.” 56th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 744, San Francisco, CA-USA, 2005.

B44. Ulger Z, Emir F, Arslan A, Idilman R, Yalcin K, Uzunalimoglu O, Bozkaya H, Bozdayi M, Yurdaydin C. “Potential role of cytokine gene polymorphisms in outcome of chronic delta hepatitis.” 57th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 677, Boston, MA-USA, 2006.

B45. Idilman R, Mizrak D, Soykan I, Corapcioglu D, Erden E, Coban S, Bektas M, Uysal AR, Emral R, Doganay B, Ozden A. “Insulin-sensitizer agents in the treatment of individuals with non-alcoholic steatohepatitis: a preliminary report.” 57th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 651, Boston, MA-USA, 2006.

B46. Kaymakoğlu S, Idilman R, Ahishali E, Onder O, Bektas M, Badur S, Bozdayi AM, Besisik F, Cakaloglu Y, Bozkaya H, Karayalcin S, Okten A, Yudraydin C. “High baseline HBV-DNA is linked to the emergence of adefovir resistance in lamivudine resistant patients.” 42th Annual Meeting of the European Association for the Study of the Liver. (EASL), 189, Barcelona, Spain, 2007.

B47. Dilsa M, Idilman R, Bektas M, Erden E, Soykan I, Corapcioglu D, Doganay B, Emral R, Uysal AR, Ozden A. “The effect of insulin-sensitizing agents in the treatment of individuals with non-alcoholic steatohepatitis.” 42th Annual Meeting of the European Association for the Study of the Liver. (EASL), 277, Barcelona, Spain, 2007.

B48. Filiz Emir, Bektas M, Kesen E, Idilman R, Bozdayi AM, Yurdaydin C. “Complete genome sequences and phylogenetic analysis of hepatitis D viruses (HDV) isolated from Turkish patients with chronic HDV infection.” 58th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 894, Boston, MA-USA, 2007.

B49. Bozkus Y, Idilman R, Mizrak D, Cengiz G, Bektas M, Ustun Y, Cınar K, Ozden A. “Lymphoproliferative disorders in chronic viral hepatitis.” 43rd Annual Meeting of the European Association for the Study of the Liver. (EASL), 239, Milan, Italy, 2007.

B50. Yurdaydin C, Idilman R, Cevik E, Akarca US, Kaymakoglu S, Bozdayi AM. “Adefovir treatment of entecavir resistance patients with lamivudine-refractory chronic hepatitis B.” 43rd Annual Meeting of the European Association for the Study of the Liver. (EASL), 255, Milan, Italy, 2007.

B51. Bektas M, Idilman R, Cerit T, Cinar K, Toruner M, Soykan I, Palabıyıkoglu M, Ozkan H, Bozkaya H, Beyler AR, Cetinkaya H, Karayalcin S, Bahar K, Ormeci N, Yurdaydin C, Dokmeci A, Ozden A. “Drug-induced liver injury: a single center experience over a 7-year period.” 59th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 368, San Francisco, CA-USA, 2008.

B52. Heidrich B, Wedemeyer H, Bektas M, Idilman R, Onder O, Bozdayi M, Zachou K, Deterding K, Raupach R, Bozkaya H, Manns MP, Yurdaydin C. “HBeAg positive delta hepatitis: virological, biochemical and clinical features in a large European Multicenter Data Base.” 59th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 1184, San Francisco, CA-USA, 2008.

B53. Karatayli S, Mizrak D, Sayki M, Ozkan M, Erden E, Yurdaydin C, Idilman R, Bozdayi M. “Potential proteomic biomarkers in assessing liver fibrozis using SELDI-TOF MS.” 44th Annual Meeting of the European Association for the Study of the Liver. (EASL), 112, Copenhagen, Denmark, 2009.

B54. Idilman R, Seval G, Cinar K, Mizrak D, Bozkus Y, Arslan M, Bektas M, Erden E, Ozden A. “The effect of dietary intervention on the long-term clinical outcome of non-alcoholic fatty liver disease” 44th Annual Meeting of the European Association for the Study of the Liver. (EASL), 371, Copenhagen, Denmark, 2009.

B55. Toy M, Onder O, Idilman R, Richardus JH, Bozdayi AM, Kuloglu Z, Kansu A, Yurdaydin C. “The burden of chronic hepatitis B in a median endemic country: a mathematical approach.” 60th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 494, Boston, MA-USA, 2009.

B56. Karatayli E, Idilman R, Karatayli S, Cevik E, Akarca U, Kaymakoglu S, Bozdayi M, Yurdaydin C. “Clonal analysis of the quasispecies of antiviral resistant HBV genomes in patients with entecavir resistance treated with rescue lamivudine-adefovir combination treatment.” 60th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 502, Boston, MA-USA, 2009.

B57. Onder FO, Yakut M, Idilman R, Seven G, Kabacam G, Karatayli E, Karatayli S, Celik Y, Bozkaya H, Bozadyi M, Yurdaydin C. “Entecavir may be beneficial in a subset of patients with chronic delta hepatitis.” 60th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 735, Boston, MA-USA, 2009.

B58. Idilman R, Seval G, Seven G, Cinar K, Mizrak D, Arslan M, Kabacam G, Ustun Y, Yakut M, Bektas M, Ozden A. “The characteristics and natural course of non-alcoholic fatty liver disease in a single center experience.” 60th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 801, Boston, MA-USA, 2009.

B59. Karatayli S, Mizrak D, Arslan M, Ozkan M, Savas B, Yurdaydin C, Idilman R, Bozdayi M. “Proteomic biomarkers in assessment of liver fibrosis using SELDI-TOF MS.” 60th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 842, Boston, MA-USA, 2009.

B60. Toy M, Onder O, Idilman R, Bozkaya H, Degertekin H, Yalcin K, Schalm SW, Yurdaydin C. “The burden of delta hepatitis projected using a mathematical model in a delta hepatitis endemic country. 60th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 929, Boston, MA-USA, 2009.

B61. Kabacam G, Onder FO, Seven G, Yakut M, Bozkaya H, Bozdayi AM, Idilman R, Yurdaydin C. “Outcome and virological changes during the follow up of a large single center cohort of chronic delta hepatitis patients” 45th Annual Meeting of the European Association for the Study of the Liver. (EASL), 318, Vienna, Austria, 2010.

B62. Lampertico P, Vigano M, Yurdaydin C, Idilman R, Buti M, Esteban R, Papatheodoridis GV, Pinzello G, Vinci M, Minola E, Suter F, Del Poggio P, Andreoletti M, Fagiuoli S, Colombo AE, Salmi A, Santantonio T, Magni C, Gubertini GA, Maldini FF, Terreni NM, Facchetti F, Soffredini R, Colombo M. “Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B.” The 61th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 369, Boston, MA-USA, 2010.

B63. Seven G, Idilman R, Bozkus Y, Cinar K, Kabacam G, Yakut M, Bozdayi AM, Yurdaydin C. “HBsAg seroconversion under lamivudine in HBeAg negative chronic hepatitis B.” The 61th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 453, Boston, MA-USA, 2010.

B64. Yakut M, Seven G, Baran B, Kabacam G, Karatayli E, Bozdayi AM, Idilman R, Kaymakoglu S, Yurdaydin C. “Clevudine treatment of chronic delta hepatitis” The 61th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 473, Boston, MA-USA, 2010.

B65. Yakut M, Bektas M, Seven G, Kabacam G, Karatayli E, Bozdayi AM, Idilman R, Yurdaydin C. “Characterization of the inactive HBsAg carrier state.” The 61th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 480, Boston, MA-USA, 2010.

B66. Seval G, Idilman R, Cinar K, Seven G, Yakut M, Kabacam G, Evranos B, Savas B, Bahar K. “Identification of risk factors for fibrosis progression in non-alcoholic fatty liver disease.” The 61th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 675, Boston, MA-USA, 2010.

B67. Kabacam G, Onder FO, Seven G, Yakut M, Bozkaya H, Bozdayi AM, Idilman R, Yurdaydin C. “Outcome of chronic delta hepatitis: experience gained from a large single center cohort.” The 61th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 751, Boston, MA-USA, 2010.

B68. Tozun N, Ozdogan OC, Cakaloglu Y, Idilman R, Karasu Z, Akarca US, Kaymakoglu S, Ergonul O. “A nationwide prevalence study and risk factors for hepatitis A, B, C and D infections in Turkey.” The 61th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 789, Boston, MA-USA, 2010.

B69. Yakut M, Bektas M, Seven G, Kabacam G, Karatayli E, Karatayli SC, Bozdayi AM, Idilman R, Yurdaydin C. “Characterization of the inactive HBsAg carrier state with 3 year follow-up.” 46th Annual Meeting of the European Association for the Study of the Liver. (EASL), 398, Berlin Germany, 2011.

B70. Kabacam G, Yakut M, Seven G, Bozkaya H, Idilman R, Yurdaydin C. “Interferon treatment of delta hepatitis: the longer duration the better the success” 46th Annual Meeting of the European Association for the Study of the Liver. (EASL), 723, Berlin Germany, 2011.

B71. Bozdayi AM, Ozturk T, Altuntas S, Karatayli SC, Karatayli E, Celik İ, Cinar K, Albayrak R, Ozkan M, Idilman R, Yurdaydin C. “Interleukin-28 (IL-28) gene polymorphism (IRS12979860 C/T) is associated with progression to chronic delta hepatitis infection.” The 62th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 512, San Francisco, CA-USA, 2011.

B72. Kabacam G, Yakut M, Seven G, Karatayli SC, Nassiri C, Bozkaya H, Bozdayi AM, Idilman R, Yurdaydin C. “Delta hepatitis may require prolonged treatment with interferon.” The 62th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 1430, San Francisco, CA-USA, 2011.

B73. Lampertico P, Soffredini R, Vigano M, Yurdaydin C, Idilman R, Papatheodoridis GV, Margariti K, Buti M, Esteban R, Zaltron S, Vavassori A, Carosi G, Minola E, Vinci M, Pinzello G, Giorgini AM, Zuin M, Salmi A, Del Poggio P, De Filppi F, Bruno S, Pasulo L, Fagiuoli S, Andreoletti M, Colli A, Maldini FF, Milanese M, Colombo AE, Bellati GA, Angeli E, Magni C, Gubertini GA, Rizzardini G, Fasano M, Santantonio T, Terreni NM, Spinzi G, Facchetti F, Invernizzi F, Testa A. “2-year effectiveness and safety of tenofovir in 302 nuc-naive patients with chronic hepatitis B: a multicenter European study in clinical practive.” The 62th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 1433, San Francisco, CA-USA, 2011.

B74. Bozdayi AM, Ozturk T, Altuntas S, Karatayli SC, Inci C, Cinar K, Albayrak R, Ozkan M, Kendal Y, Idilman R, Yurdaydin C. Interleukin-28B gene polymorphisim may affect the natural course of hepatitis B and Delta virus infections. 47th Annual Meeting of the European Association for the Study of the Liver. (EASL), 43, Barcelona, Spain, 2012.

B75. Onder FO, Kabacam G, Savas B, Ozer Etik D, Oztas E, Idilman R, Sasmaz N, Kayacetin E, Yurdaydin C. Discrepancy of treatment guidelines and liver biopsy findings in hepatitis B patients. 47th Annual Meeting of the European Association for the Study of the Liver. (EASL), 479, Barcelona, Spain, 2012.

B76. Keskin O, Ormeci A, Kabacam G, Akyuz F, Aniktar H, Karaca C, Idilman R, Kaymakoglu S, Yurdaydin C. Response to tenofovir treatment of treatment-naïve vs adefovir-resistant vs suboptimal responder patients with chronic hepatitis B. 47th Annual Meeting of the European Association for the Study of the Liver. (EASL), 520, Barcelona, Spain, 2012.

B77. Sonneveld MJ, Xie Q, Zhang NP, Zhang Q, Tabak F, Streinu-cercel A, Idilman R, De Niet A, Diculescu M, Van Vuuren AJ, Verhey E, Hansen BE, Janssen HL. Adding perginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance – first results from a global randomized trial (ARES study). The 63th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 19A, Boston, MA-USA, 2012.

B78. Yurdaydin C, Wedemeyer H, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gurel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Port K, Keskin O, Radu MN, Celen MK, Idilman R, Stift J, Mederacke I, Heidrich B, Manns MP, Dienes HP, Pegylated interferon-a-2a plus tenofovir or placebo for the treatment of hepatitis delta: first results od the HIDIT-2 study. The 63th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 24A, Boston, MA-USA, 2012.

B79. Lampertico P, Soffredini R, Vigano M, Yurdaydin C, Idilman R, Papatheodoridis GV, Margariti K, Buti M, Esteban R, Zaltron S, Vavassori A, Carosi G, Minola E, Vinci M, Pinzello G, Giorgini AM, Zuin M, Salmi A, Colombo S, Fracassetti O, Del Poggio P, Bruno S, Pasulo L, Fagiuoli S, Andreoletti M, Colli A, Maldini FF, Milanese M, Strazzabosco M, Colombo AE, Bellati GA, Angeli E, Magni C, Gubertini GA, Fasano M, Santantonio T, Terreni NM, Spinzi G, Facchetti F, Invernizzi F, Colombo M. Tenofovir monotherapy suppressed viral suppression in most filed practice, treatment-naïve patients with chronic hepatitis B followed for 3 years in a multicenter European study. The 63th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 401A, Boston, MA-USA, 2012.

B80. Keskin O, Ormeci A, Kabacam G, Akyuz F, Aniktar H, Karaca C, Idilman R, Kaymakoglu S, Yurdaydin C. Response to tenofovir treatment of treatment-naïve and adefovir experienced patients with chronic hepatitis B. The 63th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 412A, Boston, MA-USA, 2012.

B81. Onder FO, Erhardt A, Idilman R, Keskin O, Dalekos GN, Yalcin K, Manns MP, Wedemeyer H, Yurdaydin C. Can response to pegylated interferon treatment in chronic delta hepatitis be predicted with on-treatment parameter? The 63th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 436A, Boston, MA-USA, 2012.

B82. Yakut M, Keskin O, Seven G, Kabacan G, Karatayli E, Karatayli SC, Bektaş M, Bozdayi M, Idilman R, Yurdaydin C. Characterization of the inactive HBsAg carrier state with 4 years of follow-up. The 63th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 508A, Boston, MA-USA, 2012.

B83. Idilman R, Keskin O, Karatayli SC, Aniktar H, Kabacam G, Savas B, Cinar K, Bozdayi M, Bahar K, Yurdaydin C. The impact of genetic variability of patatin-like phospholipase domain-containing 3 gene on histological progression of nonalcoholic fatty liver disease: a cross-sectional and longitudinal follow-up study. The 63th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 1474A, Boston, MA-USA, 2012.

B84. Idilman IS, Keskin O, Kabacam G, Savas B, Karcaltincaba M, Cinar K, Idilman R. The impact of sequential proton density fat fraction calculation by MRI for quantification of hepatic steatosis in nonalcoholic fatty liver disease: a longitudinal follow-up study. The 63th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 1519A, Boston, MA-USA, 2012.

B85. Heidrich B, Yurdaydin C, Kabacam G, Zachou K, Bremer B, Dalekos GN, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Bock T, Idilman R, Manns MP. Long-term follow-up after PEG-IFNa2a-based therapy of chronic hepatitis delta. 48th Annual Meeting of the European Association for the Study of the Liver. (EASL), 46A, Amsterdam, The Netherland, 2013.

B86. Keskin O, Idilman R, Evranos B, Kabacam G, Turhan S, Corapcioglu D, Yurdaydin C. The effect of metformin treatment on cardiovascular risk in patients with nonalcoholic fatty liver disease. 48th Annual Meeting of the European Association for the Study of the Liver. (EASL), 1343A, Amsterdam, The Netherland, 2013.

B87. Papatheodoridis G, Dalekos GN, Yurdaydin C, Goulis I, Arends P, Buti M, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF). The 64th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 190A, Washington, DC, USA, 2013.

B88. Lampertico P, Soffredini R, Yurdaydin C, Idilman R, Papatheodoridis GV, Margariti E, Buti M, Esteban R, Zaltron S, Vavassori A, Castelli F, Vigano M, Rumi MG, Vinci M, Belli LS, Cologni G, Rizzi M, et al. Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favourable renal safety profile but does not prevent HCC in patients with or without cirrhosis. The 64th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 933A, Washington, DC, USA, 2013.

B89. Idilman R, Gunsar F, Keskin O, Meral CE, Koruk M, Gulsen MT, Elhan AH, Bozdayi AM, Akarca U, Yurdaydin C. Effectiveness and safety of entecavir and tenofovir in chronic hepatitis b patients: A multicenter Turkish Study in clinical practice. The 64th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 1029A, Washington, DC, USA, 2013.

B90. Keskin O, Yakut M, Kalkan C, Karatayli SC, Karatayli E, Idilman R, Bozadyai AM, Yurdaydin C. Inactive hepatitis B carriers are prone to HbsAg loss rather than reactivation: a 5-year prospective follow-up study. The 64th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 1057A, Washington, DC, USA, 2013.

B91. Brouwer WP, Xie Q, Sonneveld MJ, Zhang NP, Zhang Q, Tabak F, Streinu A, Wang JY, Idilman R, Reesink HW, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders JGP, Verhey E, Hansen BE, Janssen HLA. Adding peginterferon to entecavir increases response rates in HBeAg-positive chronic hepatitis B patients: Week 96 results of a global multicenter randomized trial (ARES Study). 49th Annual Meeting of the European Association for the Study of the Liver. (EASL), 2A, London, United Kingdom, 2014.

B92. Wedemeyer H, Yurdaydin C, Ernst S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gurel S, Zeuzem S, Erhardt A, Luth S, Papatheodoridis G.V, Keskin O, Port K, Radu M, Celen MK, Ildeman R, Stift J, Heidrich B, Mederacke I, Hardtke S, Koch A, Dienes HP, Manns MP. Prolonged therapy of hepatitis delta for 96 weeks with pegylated-interferon-a-2a plus tenofovir or placebo does not prevent HDVRNA relapse after treatment: THE HIDIT-2 STUDY. 49th Annual Meeting of the European Association for the Study of the Liver. (EASL), 4A, London, United Kingdom, 2014.

B93. Papatheodoridis GV, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Arends P, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Lampertico P. PAGE-B: Risk score for hepatocelular carcinoma (HCC) development in Caucasian chronic hepatitis B (CHB) patients receiving entecavir (ETV) or tenofovir (TDF). 49th Annual Meeting of the European Association for the Study of the Liver. (EASL), 1075A, London, United Kingdom, 2014.

B94. Idilman R, Keskin O, Gunsar F, Koruk M, Meral CE, Tuzun A, Gulsen M, Elhan AH, Akarca US, Yurdaydin C. Entecavir and tenofovir monotherapy in treatment naive patients with chronic hepatitis B: A multicenter Turkish study in clinical practice. 49th Annual Meeting of the European Association for the Study of the Liver. (EASL), 1087A, London, United Kingdom, 2014.

B95. Papatheodoridis GV, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis I, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Vlachogiabbajos J, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Lampertico P. Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in Caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) and tenofovir (TDF). The 65th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 233A, Boston, MA, USA, 2014.

B96. Idilman R, Akyildiz M, Keskin O, Tuzun A, Yilmaz TU, Guler N, Yaprak O, Gungor G, Erdogan Y, Dayangac M, Balci D, Cinar K, Tuzuner A, Hazinedaroglu S, Tokat Y, Ersoz S, Dokmeci A. The lobg-term efficacy of combination of nucleos(t)ide analogue treatment and low dose hepatitis B immunoglobulin on posttransplant HBV recurrence. The 65th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 703A, Boston, MA, USA, 2014.

B97. Wöbse M, Yurdaydin C, Ernst S, Hardtke S, Heidrich B, Bremer B, Keskin O, Idilman R, Koch A, Manns MP, Wedemeyer H. Eraly on-treatment HDV RNA kinetics are not predictive for long-term response to a PEG-IFNa therapy of hepatitis delta. The 65th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 1613A, Boston, MA, USA, 2014.

B98. Koh C, Yurdaydin C, Cooper S, Cory D, Dahari H, Haynes-Williams V, Winters MA, Bys M, Choong IC, Idilman R, Keskin O, Canini L, Pinto P, Wolff EF, Bishop R, Kleiner DE, Hoofnagle JH, Glenn J, Heller T. Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans. The 65th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 1860A, Boston, MA, USA, 2014.

B99. Chan HL, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R, Petersen J, Lee CM, Ma X, Caruntu FA, Tak WY, Elkhashab M, Lin L, Dinh P, Martins EB, Charuworn P, McHutchinson JG, Subramanian GM, Lim SG, Foster GR, Fung S, Morano L, Samuel D, Agarwal K, Idilman R, Strasser S, Buti M, Gaeta GB, Papatheodoridis G, Flisiak R, Marcellin P. Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon (PEG) alpha 2a combination for chronic hepatitis B (CHB). 50th Annual Meeting of the European Association for the Study of the Liver. (EASL), 117O, Vienna, Austria, 2015.

B100. Yurdaydin C, Idilman R, Choong I, Kalkan C, Keskin O, Karakaya MF, Tuzun AE, Karatayli E, Bozdayi M, Cory D, Glenn JS. Optimizing the prenylation inhibitor lonafarnib using ritonavir boosting in patients with chronic delta hepatitis. 50th Annual Meeting of the European Association for the Study of the Liver. (EASL), 118O, Vienna, Austria, 2015.

B101 Canini L, Koh C, Cotler SJ, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff E, Bishop R, Than Han MA, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H. Understanding hepatitis Delta virus and HBsAg kinetics during treatment with preynylation inhibitor lonafarnib via mathematical modeling. 50th Annual Meeting of the European Association for the Study of the Liver. (EASL), 36LP, Vienna, Austria, 2015.

B102 Papatheodoridis G, Dalekos G, Yurdaydin C, Buti M, Sypsa V, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, De La Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Excellent 5-year survival in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma. 50th Annual Meeting of the European Association for the Study of the Liver. (EASL), 641P, Vienna, Austria, 2015.

B103. Idilman IS, Tuzun A, Savas B, Idilman R, Karcaaltincaba M. Quantification of liver pancreas, kidney and vertebral body MRI-PDFF in non-alcoholic fatty liver disease. 50th Annual Meeting of the European Association for the Study of the Liver. (EASL), 1023P, Vienna, Austria, 2015.

B104. Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Lichtinghagen R, Stift J, Hardtke S, Idilman R, Keskin O, Koch A, Manns MP, Dienes HP. Non-invasive clinical scores to identify liver fibrosis in hepatitis delta patients. 51th Annual Meeting of the European Association for the Study of the Liver. (EASL), O-120, Barcelona, Spain, 2016.

B105. Yurdaydin C, Borochov N, Kalkan C, BedRoy S, Karatayli E, Haynes-Williams V, Karatayli SC, Canini L, Uprichard SL, Bozdayi AM, Choong I, Cory D, Heller T, Cotler SJ, Idilman R, Glen JS, Dahari H. Hepatitis delta virus kinetics under the prenylation inhibitor lonafarnib suggest HDV-meditated suppression of HBV replication. 51th Annual Meeting of the European Association for the Study of the Liver. (EASL), 110, Barcelona, Spain, 2016.

B106. Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glen JS, Heller T, Dahari H. Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. 51th Annual Meeting of the European Association for the Study of the Liver. (EASL), 115, Barcelona, Spain, 2016.

B107. Yurdaydın C, Idilman R, Keskin O, Kalkan C, Caliskan A, Yurdcu E, Karatayli SC, Bozdayi M, Koh C, Heller T, Glenn J. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis- end of treatment results from the LOWR HDV-2 study. 52th Annual Meeting of the European Association for the Study of the Liver. (EASL) GS-008, Amsterdam, The Netherlands, 2017.

B108. Bajaj JS, Idilman R, Mabudian L,Hood M, Fagan A, Turan D, Karakaya F, White M.Gavis E, Heuman D,Hylemon P, Atalay R, Brown R,Sikaroodi M, Gillevet P. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. 53th Annual Meeting of the European Association for the Study of the Liver. (EASL) PS-016, Paris, France, 2018.

B109. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Sypsa V, Bömmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskin O, Veelken R, Lopez‐Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Esteban R, Janssen HLA, Berg T, Lampertico P. Prediction and Need for Surveillance of Hepatocellular Carcinoma (HCC) Development after the First 5 Years of Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF) Therapy in Caucasian Chronic Hepatitis B (CHB) Patients of the PAGE‐B Cohort. The 69th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD),17, Boston, MA, USA, 2018.

B110. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Sypsa V, Bömmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskin O, Veelken R, Lopez‐Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Esteban R, Janssen HLA, Berg T, Lampertico P. ALT Levels and Risk of Hepatocellular Carcinoma (HCC) in Caucasian Chronic Hepatitis B (CHB) Patients Under Long‐Term Therapy with Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF). The 69th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD),17, Boston, MA, USA, 2018.

B111. Cox IJ, Idilman R, Fagan A, Turan D, Ajayi L, Karakaya F, Williams R, Gavis E, Andrew Atkinson R, Guennec AL, Taylor-Robinson S, Sikaroodi M, Gillevet P, Bajaj JS. Plasma metabolomic changes modulate the impact of Middle Eastern versus Western Diet in an international cirrhosis cohort. 54th Annual Meeting of the European Association for the Study of the Liver. (EASL) PS-082, Vienna, Austria France, 2019.

B112. Hardtke S, Wedemeyer H, Caruntu FA, Curescu M, Kendal Y, Akarca U, Yurdcu E, Gurel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis G, Keskin O, Port K, Radu M, Tabak F, Idilman R, Bozdayi M, Koch A, Manns MP, Cornberg M, Yurdaydin C. Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study. 54th Annual Meeting of the European Association for the Study of the Liver. (EASL) FRI-175, Vienna, Austria France, 2019.

B113. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Sypsa V, Bömmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez‐Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Esteban R, Janssen HLA, Berg T, Lampertico P. Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients. 54th Annual Meeting of the European Association for the Study of the Liver. (EASL) FRI-197, Vienna, Austria France, 2019.

B114. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Sypsa V, Bömmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Keskin O, Veelken R, Lopez‐Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Esteban R, Janssen HLA, Berg T, Lampertico P. Similar Risk Of Hepatocellular Carcinoma Development During Long‐Term Entecavir or Tenofovir Disoproxil Fumarate Therapy In Caucasian Chronic Hepatitis B Patients. The 70th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 454, Boston, MA, USA, 2019.

B115. Sah FT, Keskin O, Yurdcu E, Yilmaz Y, Karakaya MF, Kartal A, Bozdayi M, Idilman R, Yurdaydin C. Treatment Discontinuation In HBeAg‐Negative Chronic Hepatit B is a Viable Option in Non‐Cirrhotic Genotype D Chronic Hepatitis B Patients. The 70th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 482, Boston, MA, USA, 2019.

B116. Yurdaydin C, Keskin O, Yurdcu E, Yakut M, Seven G, Kabacam G, Onder FA, Bektas M, Bozdayi M, Idilman R. Natural History of Inactive HBsAg Carriers: A 10‐ Year Prospective Follow‐Up Study. The 70th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 954, Boston, MA, USA, 2019.

B117. Ulas BB, Ozyuncu N, Calıskan Kartal A, Peker E, Turan Gokce D, Gumussoy M, Ozercan M, Tulunay C, Uzun C, Erden A, Turhan S, Idilman R. Association between Non‐Alcoholic Fatty Liver Disease and Subclinical Atherosclerosis and Myocardial Dysfunction Using Multimodality Imaging Follow‐Up Study. The 70th Annual Meeting, The American Association For The Study Of Liver Diseases (AASLD), 2313, Boston, MA, USA, 2019.